<DOC>
	<DOC>NCT02581202</DOC>
	<brief_summary>This study seeks to assess the virologic effectiveness of dual therapy (lopinavir/ ritonavir (LPV/r) + lamivudine (3TC)) in treatment-experienced human immunodeficiency virus 1 (HIV-1) infected participants with an undetectable plasma HIV-1 (ribonucleic acid) RNA level (for at least 6 months) at the 48 week time point of treatment in the routine clinical settings of the Russian Federation.</brief_summary>
	<brief_title>The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>1. Age 18 years and older (male and female). 2. HIV1 infected patients on any triple HAART with plasma HIV1 RNA level &lt;50 copies/mL for at least 6 months (two consequently plasma HIV1 RNA levels) transferred as medically appropriate to LPV/r + 3TC as decided by the physician in the routine clinical settings. OR HIV1 infected patients who were switched on the dual therapy (LPV/r + 3TC) no more than 60 days ago. 3. Cumulative HAART experience at least 6 months. 4. Authorization (Consent) for Use/Disclosure of Data signed by the patient. 1. Contraindications to lopinavir/ritonavir and lamivudine 2. Previous participation in this program</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>antiretroviral therapy</keyword>
</DOC>